Alpine Immune Sciences's competitors

Alpine Immune Sciences's competitors include Invectys, OSE Immunotherapeutics, X4 Pharmaceuticals and GTx
Add company...
Alpine Immune Sciences
Modern therapies targeting the immune synapse.
Invectys
Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers.
OSE Immunotherapeutics
OSE Immunotherapeutics (Nantes – ISIN : FR0012127173 ; Mnemo : OSE) was created in May 2016 through the merger of OSE Pharma, an immuno-oncology company developing specific immunotherapy activating T lymphocytes, and Effimune, a biotechnology company specializing in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
GTx
GTx, Inc is a pharmaceutical company and developer of drugs that utilize hormonal pathways.
Founding Date
Founding Date
2015
Founding Date
2010
Founding Date
2012
Founding Date
2012
Founding Date
1997
Type
Type
Private
Type
Private
Type
Public
Type
Private
Type
Public
Tags
Locations
Locations
Seattle, US HQ
Locations
Paris, FR HQ
Locations
Nantes, FR HQ
Paris, FR
Locations
Cambridge, US HQ
Locations
Memphis, US HQ
Employees
Employees
N/A
Employees
138% increase
Employees
2618% increase
Employees
274% increase
Employees
26
Valuation ($)
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
60.5 m
Valuation ($)
N/A
Valuation ($)
468.4 m

Funding

Latest funding round
Latest funding round
$ 48m (almost 2 years ago)
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 27m (6 months ago)
Latest funding round
N/A
Total funding raised
Total funding raised
$ 49.3m
Total funding raised
$ 4.7m
Total funding raised
$ 10.3m
Total funding raised
$ 64.5m
Total funding raised
$ 64.7m
For sources of this data, please see the company profileDownload Excel

View company profiles

Invectys
HQ
Paris, FR
Employees
13↑ 8% increase

Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers.

View company
OSE Immunotherapeutics
HQ
Nantes, FR
Employees
26↑ 18% increase

OSE Immunotherapeutics (Nantes – ISIN : FR0012127173 ; Mnemo : OSE) was created in May 2016 through the merger of OSE Pharma, an immuno-oncology company developing specific immunotherapy activating T lymphocytes, and Effimune, a biotechnology company specializing in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology.

View company
X4 Pharmaceuticals
HQ
Cambridge, US
Employees
27↑ 4% increase

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.

View company
GTx
HQ
Memphis, US
Employees
26

GTx, Inc is a pharmaceutical company and developer of drugs that utilize hormonal pathways.

View company